
ASH 2021: Pembrolizumab Plus HDAC Inhibition Exhibits High Response Rates for Hodgkin Lymphoma in Early Study
Response rates to pembrolizumab (Keytruda) plus vorinostat (Zolinza), a histone deacetylase (HDAC) inhibitor, were high in anti-PD1 naïve/sensitivity relapsed/refractory Hodgkin lymphoma (HL), according to a study funded in part by LRF and presented by LRF grantee Alex F. Herrera, MD, of City of Hope.






